India rejects teneligliptin salts patent

India has rejected Mitsubishi Tanabe's patent application relating to certain salts of teneligliptin, the dipeptidyl peptidase-4 (DPP-4) inhibitor currently in the news after the arrival of a cut-price generic version on the domestic market.

More from Alimentary/Metabolic

More from Therapy Areas